Company

Scorpion Therapeutics, Inc.

Scorpion Therapeutics develops targeted cancer therapies through precision oncology research.

About

Founded in 2020 and based in Boston, US, Scorpion Therapeutics develops targeted therapies for cancer. Its pipeline includes STX-478, a mutant-selective PI3Ka inhibitor in a Phase 1/2 trial for breast cancer and other advanced solid tumors, as well as other clinical and discovery-stage programs. Eli Lilly and Company Limited acquired Scorpion for USD 2.5 billion on January 13, 2025.

3Funding rounds

16Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in